CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 11,316 enrolled
Drug / intervention
Furoate/Umeclidinium/Vilanterol +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05127304
NCT05127304N/ACompleted
CompareCT.gov

Health Care Resource Utilization, Cost and Other Outcomes of Patients Diagnosed With COPD Initiating Tiotropium Bromide/Olodaterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol

Boehringer Ingelheim·observational·Posted Nov 19, 2021·Updated Nov 13, 2023

In Brief

An observational study evaluating Trelegy Ellipta, Stiolto Respimat, and 2 other interventions for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 11,316 participants across 1 site.

Detailed Summary

The purpose of this study is to estimate disease-related and all-cause burden and clinical outcomes of interest following initiation of chronic obstructive lung disease (COPD) maintenance therapy with Tiotropium Bromide/Olodaterol (TIO/OLO) or Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedNov 19, 2021
Enrollment StartFeb 26, 2021
Primary CompletionFeb 3, 2022
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 4.6 years ago

Interventions

Trelegy Elliptadevice

Trelegy Ellipta with Furoate/Umeclidinium/Vilanterol

Stiolto Respimatdevice

Stiolto Respimat with Tiotropium Bromide/Olodaterol

Furoate/Umeclidinium/Vilanteroldrug

Furoate/Umeclidinium/Vilanterol

Tiotropium Bromide/Olodateroldrug

Tiotropium Bromide/Olodaterol